July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Expression of cysteinyl leukotriene receptors 1 and 2 in uveal melanoma
Author Affiliations & Notes
  • Paulina Garcia de Alba Graue
    The MUHC-McGill University Ocular Pathology & Translational Research Laboratory., Montreal, Quebec, Canada
  • Alicia Goyeneche
    The MUHC-McGill University Ocular Pathology & Translational Research Laboratory., Montreal, Quebec, Canada
  • Jacqueline Coblentz
    The MUHC-McGill University Ocular Pathology & Translational Research Laboratory., Montreal, Quebec, Canada
  • Tadhg Ferrier
    The MUHC-McGill University Ocular Pathology & Translational Research Laboratory., Montreal, Quebec, Canada
  • Miguel N Burnier
    The MUHC-McGill University Ocular Pathology & Translational Research Laboratory., Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships   Paulina Garcia de Alba Graue, None; Alicia Goyeneche, None; Jacqueline Coblentz, None; Tadhg Ferrier, None; Miguel Burnier, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 757. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paulina Garcia de Alba Graue, Alicia Goyeneche, Jacqueline Coblentz, Tadhg Ferrier, Miguel N Burnier; Expression of cysteinyl leukotriene receptors 1 and 2 in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2019;60(9):757. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Uveal melanoma (UM) is the most common primary intraocular malignancy in adults and expresses frequent driver mutations in GNAQ and GNA11 genes, both of which are activated by the cysteinyl leukotriene receptor 2 (CYSLTR2) and are downstream effectors of MAPK/MEK/ERK signaling pathway. Overexpression of cysteinyl leukotriene receptors are linked with cancer processes such as neoangiogenesis, sustained proliferative signaling, migration and invasion. The aim of this study is to analyze the expression both CYSLTR1 and CYSLTR2 and further investigate their potential as therapeutic targets in UM.

Methods : In total, 10 UM were evaluated. Immunohistochemistry was performed using the Ventana Benchmark Automated Platform on paraffin-embedded samples using polyclonal anti-CYSLTR1 and polyclonal anti-CYSLTR2 antibodies. Slides were digitized using the Aperio Scanscope Scanner. Expression was evaluated using an Immunoreactive Score as follows: intense cytoplasm staining in malignant cells (2+); mild staining in the cytoplasm of malignant cells (1+), no staining in the cytoplasm of malignant cells (0), and further subclassified by the extent of staining as localized (1+) or diffuse (+2). Statistical analysis was performed using Fischer’s Exact Test; P<0.05 was considered significant.

Results : CYSLTR1 expression was positive in all 10 UM. In 8 UM (80%), the score was 2-4, while a score of 0-1 was obtained in 2 UM (20%). CYSLTR2 expression was positive in 9 samples of UM. In 6 UM (60%), the score was 2-4, while a score of 0-1 was obtained in 4 UM (40%). The extent of both CYSLTR1 and CYSLTR2 expression was predominantly localized (~60%). The normal uveal tract scored 0-1 in 8 samples, and a score of 2-4 in 2 samples. Both CYSLTR1 (P=0.023) and CYSLTR2 (P=0.0108) expression in UM was statistically higher when compared to the normal uveal tract. A tendency of intense staining of both CYSLTR1 and CYSLTR2 in the areas where the number of infiltrating melanophages was higher was also observed.

Conclusions : To the best of our knowledge, this is the first study to analyze the expression of both CYSLTR1 and CYSLTR2 in UM. Our study demonstrates that both CYSLTR1 and CYSLTR2 expression is statistically significant in UM when compared to the normal uveal tract, thus supporting their association in the malignant transformation of this tumor. Further investigation of CYSLTRs as potential therapeutic targets in UM is warranted.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×